GSK will present its latest gynaecological cancer research at the European Society for Medical Oncology (ESMO) Congress 2022 (September 9-13).
The company will share positive trial data on its gynaecological cancer treatments Zejula (niraparib) and Jemperli (dostarlimab), as well as early-stage research in immuno-oncology and real-world evidence assessing treatment patterns and outcomes.
Hesham Abdullah, SVP, Global Head of Oncology Development, GSK said: “The long-term data we are presenting at ESMO further our understanding of the role of Zejula and Jemperli to treat certain ovarian and endometrial cancers and will provide the oncology community with deeper insights to inform treatment decisions and help optimise outcomes for patients.”
Positive data will be presented from the Phase III PRIMA study evaluating niraparib as a maintenance monotherapy in patients with first-line ovarian cancer following a response to platinum-based chemotherapy.
Updated results from the GARNET trial will further demonstrate the potential of dostarlimab, a programmed cell death receptor-1 (PD-1) blocking antibody, in the treatment of advanced solid tumours.
GSK will also present a real-world analysis of patients with dMMR/microsatellite instability-high (MSI-H) endometrial cancer who received early access to dostarlimab via the temporary authorisation for use (ATU) programme in France, highlighting the need for patient access to new treatment regimens.
